Indivior Pharmaceuticals (INDV) Asset Writedowns and Impairment (2024 - 2026)

Indivior Pharmaceuticals' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $25.0 million (up 257.14% YoY), while the FY2025 annual figure was $19.0 million, up 137.5% from the prior year.
• Asset Writedowns and Impairment was $6.0 million for Q1 2026 at Indivior Pharmaceuticals, up from $3.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $16.0 million in Q3 2025 to a low of $1.0 million in Q1 2024.
• Historically, Asset Writedowns and Impairment has averaged $6.6 million across 3 years, with a median of $6.0 million in 2026.